Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

Blood (2025) 146 (Supplement 1): 77.

https://doi.org/10.1182/blood-2025-77

Published: 2025

Journal Articles

A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia

Vincent Alcazer, Stéphanie Dulucq, Isabelle Mosnier, Kaddour Chabane, Pauline Bertin-Mourot, Sandrine Derruau, Marie Balsat, Hélène Labussière-Wallet, Pierre Sujobert, François-Xavier Mahon, Gabriel Etienne, Franck Nicolini, Sandrine Hayette

Blood (2025) 146 (Supplement 1): 76.

https://doi.org/10.1182/blood-2025-76

Published: 2025

Journal Articles

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.

Blood (2025) 146 (Supplement 1): 5567.

https://doi.org/10.1182/blood-2025-5567

Published: 2025

Journal Articles

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Blood (2025) 146 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2025-1993

Published: 2025

Journal Articles

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

Franck Nicolini, Francoise Huguet, Aude Charbonnier, Martine Escoffre-Barbe, Gabrielle Roth-Guepin, Shanti Amé, Emilie Cayssials, Mathieu Meunier, Charlotte Doublet, Vincent Alcazer, Stéphane Morisset, Romaine Mayet, Gwenaëlle Garin, Gabriel Etienne, Ivan Sloma, Olivier Mansier, Stéphanie Dulucq

Blood (2025) 146 (Supplement 1): 3773.

https://doi.org/10.1182/blood-2025-3773

Published: 2025

Journal Articles

Sequential monitoring using NGS allows detection of ABL1 KD mutations in patients with chronic Phase CML: Results from the prospective calls trial

Ipek Baymul, Peter Edel, Sophie Jackson, Kate Rothwell, Heather Oakervee, Belsham Edward, Franck Nicolini, Sebastian Francis, Jenny Byrne, Joanne Ewing, Laura-Li Gagnon, Nicholas Lea, Aytug Kizilors, Hugues de Lavallade

Blood (2025) 146 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2025-2007

Published: 2025

Journal Articles

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

Fadi Haddad, Hagop Kantarjian, Mauricette Michallet, Christophe Bouvier, Ghayas Issa, Koji Sasaki, Julien Bollard, Julie Hildt, Sara Dellasala, Vincent Alcazer, Elias Jabbour, Franck Nicolini

Blood (2025) 146 (Supplement 1): 5550.

https://doi.org/10.1182/blood-2025-5550

Published: 2025

Journal Articles

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Catherine Roche-Lestienne, Marceau Alice, Elise Labis, Olivier Nibourel, Valérie Coiteux, Joelle Guilhot, Laurence Legros, MD, Franck Nicolini, MD, PhD, Philippe Rousselot, MD, PhD, Martine Gardembas, Nathalie Helevaut, Cécile Frimat, Francois Guilhot, Claude Preudhomme

Blood (2010) 116 (21): 3377.

https://doi.org/10.1182/blood.V116.21.3377.3377

Published: 2010

Journal Articles

Allogeneic Stem Cell Transplantation for Blast Crisis (BC) Chronic Myelogenous Leukemia (CML) In the Tyrosine Kinase Inhibitors (TKIs) Era. Analysis of Pre-Transplant Variables on Transplant Outcome. On Behalf of the Societe Française De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML

Blood (2010) 116 (21): 2266.

https://doi.org/10.1182/blood.V116.21.2266.2266

Published: 2010

Journal Articles

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Xiaoyan Jiang, Donna Forrest, Franck Nicolini, Ali Turhan, Joelle Guilhot, Calvin Yip, Tessa Holyoake, Heather Jorgensen, Karen Lambie, Kyi Min Saw, Emily Pang, Ranko Vukovic, Paeta Lehn, Ashley Ringrose, Miao Yu, Ryan R. Brinkman, Clay Smith, Allen Eaves, Connie Eaves

Blood (2010) 116 (12): 2112–2121.

https://doi.org/10.1182/blood-2009-05-222471

Published: 2010

Includes: Supplemental data

Journal Articles

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Franck Nicolini, MD, PhD, Laurence Legros, MD, PhD, Lydia Roy, MD, PhD, Jean-Claude Chomel, MD, Kaddour Chabane, BSc, Sophie Ducastelle, MD, Selim Corm, MD, Mauricette Michallet, MD, PhD, Francois Guilhot, MD, Ali Turhan, MD, PhD, Sandrine Hayette, PhD

Blood (2008) 112 (11): 1103.

https://doi.org/10.1182/blood.V112.11.1103.1103

Published: 2008

Journal Articles

Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Patients with High-Risk AML in First CR: The ALFA-0702 Pilot Study.

Xavier Thomas, Ida Lobe, Emmanuel Raffoux, Nicolas Boissel, Quoc-Hung Le, Franck Nicolini, Adrienne de Labarthe, Sandrine Hayette, Jean-Michel Cayuela, Hervé Dombret

Blood (2008) 112 (11): 1934.

https://doi.org/10.1182/blood.V112.11.1934.1934

Published: 2008

Journal Articles

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

Franck Nicolini, MD, Giuliana Alimena, MD, Haifa-Kathrin Al-Ali, MD, Andrey Zaritskey, Zhixiang Shen, MD, Saengsuree Jootar, MD, Graeme Smith, MD, Yanzhi Hsu, Maria Luisa Veronese, David A. Rizzieri

Blood (2007) 110 (11): 2960.

https://doi.org/10.1182/blood.V110.11.2960.2960

Published: 2007

Journal Articles

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

Xiaoyan Jiang, MD, PhD, Donna Forrest, MD, Franck Nicolini, MD, PhD, Karen Lambie, Kyi Min Saw, Emily Pang, Ranko Vukovic, Clayton Smith, MD, Allen Eaves, MD, PhD, Connie Eaves, PhD

Blood (2007) 110 (11): 324.

https://doi.org/10.1182/blood.V110.11.324.324

Published: 2007

Journal Articles

Imatinib Mesylate Dose Escalation Improves Disease Response in Chronic-Phase Chronic Myeloid Leukaemia Patients after Cytogenetic or Molecular Suboptimal Responses to Standard Doses of Imatinib.

Delphine Rea, MDPhD, Gabriel Etienne, MD, Selim Corm, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Francois-Xavier Mahon, MDPhD, Franck Nicolini, MDPhD

Blood (2007) 110 (11): 1052.

https://doi.org/10.1182/blood.V110.11.1052.1052

Published: 2007

Journal Articles

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Nicholas Heaney, Mark Drummond, Jaspal Kaeda, Franck Nicolini, Richard Clark, George Wilson, Pat Shepherd, Jane Tighe, Lorna McLintock, Timothy Hughes, Tessa L. Holyoake

Blood (2007) 110 (11): 1033.

https://doi.org/10.1182/blood.V110.11.1033.1033

Published: 2007

Journal Articles

Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP).

Andreas Hochhaus, Francis J. Giles, Philipp le Coutre, Michele Baccarani, Norbert Gattermann, Kapil N. Bhalla, Giuliana Alimena, Gert Ossenkoppele, Franck Nicolini, Mark R. Litzow, Ravi Bhatia, Francisco Cervantes, Jim Wang, Richard Woodman, Jorge Cortes, Hagop Kantarjian

Blood (2007) 110 (11): 1038.

https://doi.org/10.1182/blood.V110.11.1038.1038

Published: 2007

Journal Articles

High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.

Philippe Rousselot, Franck Nicolini, François Xavier Mahon, Delphine Réa, Jérome Jaubert, Christian Berthou, Josy Reiffers, Joelle Guilhot, François Guilhot

Blood (2007) 110 (11): 1039.

https://doi.org/10.1182/blood.V110.11.1039.1039

Published: 2007

Journal Articles

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Catherine Roche-Lestienne, PhD, Laureline Deluche, MD, Selim Corm, MD, Isabelle Tigaud, MD, Sami Joha, PhD, Nathalie Philippe, PhD, Sandrine Geffroy, PhD, Jean-Luc Lai, PhD, Franck Nicolini, MD, PhD, Claude Preudhomme, MD, PhD

Blood (2007) 110 (11): 2786.

https://doi.org/10.1182/blood.V110.11.2786.2786

Published: 2007

Journal Articles

European Sub-Registry of Chronic Myelogenous Leukemia (CML) Patients (pts) in Failure after Imatinib Therapy (IFP): Rationale, Study Design and Current Enrollment.

Joelle Guilhot, Florence Tartarin, Markus Pfirmann, Arnon Nagler, Franck Nicolini, Philippe Rousselot, Kimmo Porkka, Gert Ossenkoppele, Jesper Stentoft, Francisco Cervantes, Gianantonio Rosti, Josef Thaler, Philipp le Coutre, Joerg Hasford, Rudiger Hehlmann, Francois Guilhot, European LeukemiaNet

Blood (2006) 108 (11): 4764.

https://doi.org/10.1182/blood.V108.11.4764.4764

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

Sequential monitoring using NGS allows detection of ABL1 KD mutations in patients with chronic Phase CML: Results from the prospective calls trial

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Patients with High-Risk AML in First CR: The ALFA-0702 Pilot Study.

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

Imatinib Mesylate Dose Escalation Improves Disease Response in Chronic-Phase Chronic Myeloid Leukaemia Patients after Cytogenetic or Molecular Suboptimal Responses to Standard Doses of Imatinib.

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP).

High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

European Sub-Registry of Chronic Myelogenous Leukemia (CML) Patients (pts) in Failure after Imatinib Therapy (IFP): Rationale, Study Design and Current Enrollment.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only